Trial Profile
Predictive factors associated with virological response in Daclatasvir and Asunaprevir combination therapy for genotype1b-infected chronic hepatitis C patients : multicenter study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2015 New trial record